Search

Your search keyword '"Sánchez‐Soblechero, Antonio"' showing total 5 results
Start Over Author "Sánchez‐Soblechero, Antonio" Publisher wiley
5 results on '"Sánchez‐Soblechero, Antonio"'

1. Evaluation of the concomitant use of prophylactic treatments in patients with migraine under anti‐calcitonin gene‐related peptide therapies: The PREVENAC study

Author

Gago‐Veiga, Ana Beatriz, primary, Lopez‐Alcaide, Noelia, additional, Quintas, Sonia, additional, Fernández Lázaro, Iris, additional, Casas‐Limón, Javier, additional, Calle, Carlos, additional, Latorre, Germán, additional, González‐García, Nuria, additional, Porta‐Etessam, Jesús, additional, Rodriguez‐Vico, Jaime, additional, Jaimes, Alex, additional, Gómez García, Andrea, additional, García‐Azorín, David, additional, Guerrero‐Peral, Ángel Luis, additional, Sierra, Álvaro, additional, Lozano Ros, Alberto, additional, Sánchez‐Soblechero, Antonio, additional, Díaz‐de‐Teran, Javier, additional, Membrilla, Javier A., additional, Treviño, Cristina, additional, and Gonzalez‐Martinez, Alicia, additional

Published
2024
Full Text
View/download PDF

2. Translating NIA‐AA criteria into usual practice: Report from the ReDeMa Project

Author

Sánchez‐Soblechero, Antonio, primary, Berbel, Angel, additional, Villarejo, Alberto, additional, Palmí‐Cortés, Itziar, additional, Vieira, Alba, additional, Gil‐Moreno, María José, additional, Fernández, Cristina, additional, Martín‐Montes, Ãngel, additional, Carreras, María Teresa, additional, Fernández, Yolanda, additional, Puertas, Carolina, additional, Blanco‐Palmero, Victor, additional, Llamas, Sara, additional, González‐Sánchez, Marta, additional, Lapeña, Teresa, additional, de Luis, Pilar, additional, Manzano, Sagrario, additional, and Olazarán, Javier, additional

Published
2024
Full Text
View/download PDF

3. Neurological complications of COVID‐19 in hospitalized patients: The registry of a neurology department in the first wave of the pandemic

Author

Portela‐Sánchez, Sofía, primary, Sánchez‐Soblechero, Antonio, additional, Melgarejo Otalora, Pedro José, additional, Rodríguez López, Ángela, additional, Velilla Alonso, Gabriel, additional, Palacios‐Mendoza, Michael Armando, additional, Cátedra Caramé, Carlos, additional, Amaya Pascasio, Laura, additional, Mas Serrano, Miguel, additional, Massot‐Tarrús, Andreu, additional, De La Casa‐Fages, Beatriz, additional, Díaz‐Otero, Fernando, additional, Catalina, Irene, additional, García Domínguez, Jose Manuel, additional, Pérez‐Sánchez, Javier Ricardo, additional, Muñoz‐Blanco, José Luis, additional, and Grandas, Francisco, additional

Published
2021
Full Text
View/download PDF

5. RE-START: Exploring the effectiveness of anti-calcitonin gene-related peptide resumption after discontinuation in migraine.

Author

Romero Del Rincón C, Gonzalez-Martinez A, Quintas S, García-Azorín D, Fernández Lázaro I, Guerrero-Peral AL, Gonzalez Osorio Y, Santos-Lasaosa S, González Oria C, Sánchez Rodríguez N, Iglesias Díez F, Echavarría Íñiguez A, Gil Luque S, Huerta-Villanueva M, Campoy Díaz S, Muñoz-Vendrell A, Lozano Ros A, Sánchez-Soblechero A, Velasco Juanes F, Kortazar-Zubizarreta I, Echeverría A, Rodríguez-Vico J, Jaimes Sánchez A, Gómez García A, Morollón Sánchez-Mateos N, Belvis R, Navarro Pérez MP, García-Moncó JC, Álvarez Escudero MR, Montes N, and Gago-Veiga AB

Subjects
Humans, Female, Adolescent, Male, Prospective Studies, Headache, Antibodies, Monoclonal, Calcitonin Gene-Related Peptide, Migraine Disorders
Abstract

Background and Purpose: According to the latest European guidelines, discontinuation of monoclonal antibodies against calcitonin gene-related peptide (anti-CGRP MAb) may be considered after 12-18 months of treatment. However, some patients may worsen after discontinuation. In this study, we assessed the response following treatment resumption., Methods: This was a prospective study conducted in 14 Headache Units in Spain. We included patients with response to anti-CGRP MAb with clinical worsening after withdrawal and resumption of treatment. Numbers of monthly migraine days (MMD) and monthly headache days (MHD) were obtained at four time points: before starting anti-CGRP MAb (T-baseline); last month of first treatment period (T-suspension); month of restart due to worsening (T-worsening); and 3 months after resumption (T-reintroduction). The response rate to resumption was calculated. Possible differences among periods were analysed according to MMD and MHD., Results: A total of 360 patients, 82% women, with a median (interquartile range [IQR]) age at migraine onset of 18 (12) years. The median (IQR) MHD at T-baseline was 20 (13) and MMD was 5 (6); at T-suspension, the median (IQR) MHD was 5 (6) and MMD was 4 (5); at T-worsening, the median (IQR) MHD was 16 (13) and MMD was 12 (6); and at T-reintroduction, the median (IQR) MHD was 8 (8) and MHD was 5 (5). In the second period of treatment, a 50% response rate was achieved by 57.4% of patients in MHD and 65.8% in MMD. Multivariate models showed significant differences in MHD between the third month after reintroduction and last month before suspension of first treatment period (p < 0.001)., Conclusion: The results suggest that anti-CGRP MAb therapy is effective after reintroduction. However, 3 months after resumption, one third of the sample reached the same improvement as after the first treatment period., (© 2024 The Authors. European Journal of Neurology published by John Wiley & Sons Ltd on behalf of European Academy of Neurology.)

Published
2024
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results